Stories

For too long, modern medicine has treated diseases as if they were uniform, defined by a label rather than by their underlying biology. Today, we have an unprecedented ability to interrogate the molecular drivers that shape each person’s cancer, and in doing so, we’re transforming how we diagnose, develop and deliver the medicines that matter most.

At the heart of Ipsen’s early discovery efforts is a question of fit—how a molecule interacts with a disease-relevant protein, and what that means for therapeutic potential. Alexis Cocozaki’s team focuses on that exact space, applying biophysical and structural biology techniques to evaluate and optimize new assets at the atomic level. 

Working in early development, I have the privilege to see the next generation of therapeutic science take shape – and few areas are more compelling than immuno-oncology (I-O). From first data points in the lab to breakthroughs in the clinic, it is clear that we are entering a new era with the potential to deliver transformative outcomes for patients.

Late-stage partnering is unforgiving — high-stakes, capital-intensive, and fiercely competitive. The cost of a poor partnership isn’t just financial; it’s the lost opportunity to advance a program that could have changed patient outcomes but didn’t get the right partner at the right moment.

For many people at Ipsen, the impact of their work becomes clear through patient stories, scientific breakthroughs, or moments shared with colleagues. For Emilie Manier, Senior Executive Assistant, that realization came in a much more unexpected situation: a dinner with friends.